SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-16-671974
Filing Date
2016-08-04
Accepted
2016-08-04 17:01:51
Documents
55
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d190141d10q.htm 10-Q 566030
2 EX-31.1 d190141dex311.htm EX-31.1 5836
3 EX-31.2 d190141dex312.htm EX-31.2 5832
4 EX-32.1 d190141dex321.htm EX-32.1 3760
11 GRAPHIC g190141g72x53.jpg GRAPHIC 122859
  Complete submission text file 0001193125-16-671974.txt   2925446

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ntla-20160630.xml EX-101.INS 393993
6 XBRL TAXONOMY EXTENSION SCHEMA ntla-20160630.xsd EX-101.SCH 36491
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20160630_cal.xml EX-101.CAL 44288
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20160630_def.xml EX-101.DEF 101427
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20160630_lab.xml EX-101.LAB 294094
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20160630_pre.xml EX-101.PRE 201893
Mailing Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139
Business Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 161808257
SIC: 2835 In Vitro & In Vivo Diagnostic Substances